Journal of Shandong University (Health Sciences) ›› 2025, Vol. 63 ›› Issue (10): 61-71.doi: 10.6040/j.issn.1671-7554.0.2025.0030

• Clinical Medicine • Previous Articles    

The role of lncRNA PVT1 in prognostic assessment and malignant progression of gastric cancer: a study based on nomogram model and functional cellular experiments

CHEN Wenliang1, WANG Huanhuan2, HAO Jinjin3, GONG Rui3, ZHAO Qiang3, ZHANG Fei3, GAO Lei3, DONG Jingxun4   

  1. 1. Department of General Surgery, The 2nd Affiliated Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi, China;
    2. Department of General Surgery, Jincheng Peoples Hospital, Jincheng 048026, Shanxi, China;
    3. Graduate Department of Shanxi Medical University, Taiyuan 030001, Shanxi, China;
    4. Department of Minimal Invasive Digestive Surgery, Shanxi Provincial Cancer Hospital, Taiyuan 030013, Shanxi, China
  • Published:2025-10-17

Abstract: Objective To explore the prognostic value of the long noncoding RNA plasmacytoma variant translocation 1(lncRNA PVT1)nomogram model in predicting postoperative survival in patients with gastric cancer(GC), and to investigate the effects of lncRNA PVT1 on the proliferation and invasion of GC cells. Methods A quantitative real-time polymerase chain reaction(RT-qPCR)was employed to measure the expression levels of lncRNA PVT1 and c-Myc in GC tissues and paired gastric mucosa tissues from 196 patients. The expression of c-Myc protein in GC tissues was detected using the western blotting technique. The investigation involved the implementation of survival analysis and Cox regression analysis, with the objective of elucidating the clinicopathological factors associated with GC and the construction of a prognostic model. In vitro, MGC-803 cells were subjected to transfection with a specific interfering RNA(siRNA)designed to target lncRNA PVT1. The experimental design involved the establishment of three distinct groups: the experimental group, which received the targeted knockdown via the PVT1-siRNA, the control group, which received a non-specific negative control via the PVT1-siRNA, and a third group that served as a blank control, receiving no transfection. The expression of c-Myc protein in GC cells was measured using Western blotting, while cell proliferation and invasion were evaluated using CCK-8 and Transwell assays, respectively. Results The expression of lncRNA PVT1(P=0.002), along with c-Myc mRNA expression(P=0.013)and protein levels(P=0.024), was significantly elevated in GC tissues compared to adjacent normal tissues. Univariate survival analysis and multivariate Cox regression analysis identified several factors significantly correlated with overall survival(OS)in GC patients, including age(P=0.004), and Laurens classification(P=0.021). The following factors were found to be statistically significant: local tumor invasion(P<0.001), pTNM stage(P=0.020), local lymph node metastasis(P=0.002), and the expression level of lncRNA PVT1(P<0.001). The expression level of lncRNA PVT1 was found to be an independent risk factor. The nomogram model based on lncRNA PVT1 predicted 1-year, 2-year, and 3-year OS probabilities of 0.997, 0.937, and 0.828, respectively. Furthermore, following the silencing of lncRNA PVT1, a significant reduction in both c-Myc mRNA(P<0.001)and protein levels(P=0.006)was observed, as well as a reduction in cell proliferation(P<0.001)and invasion ability(P=0.028)in the siPVT1-1907 group compared to the siNC group. Conclusion The present study has showed that the expression of lncRNA PVT1 is elevated in cases of gastric cancer, and that this elevation is associated with a poor prognosis for patients. The lncRNA PVT1-based nomogram model demonstrates good predictive capability for postoperative survival in GC. Additionally, lncRNA PVT1 appears to promote carcinogenesis by upregulating c-Myc expression in GC cells. This finding indicates that the lncRNA PVT1-Myc regulatory network may represent a viable target for the clinical management of gastric cancer.

Key words: Plasmacytoma variant translocation 1, Gastric cancer, Prognosis, Nomogram, Oncogene Myc, RNA interference

CLC Number: 

  • R735.2
[1] López MJ, Carbajal J, Alfaro AL, et al. Characteristics of gastric cancer around the world[J]. Crit Rev Oncol Hematol, 2023, 181: 103841. doi: 10.1016/j.critrevonc.2022.103841
[2] Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer[J]. Lancet, 2020, 396(10251): 635-648.
[3] Li RM, Wang X, Zhu CM, et al. lncRNA PVT1: a novel oncogene in multiple cancers[J]. Cell Mol Biol Lett, 2022, 27(1): 84. doi: 10.1186/s11658-022-00385-x
[4] Hakami MA, Hazazi A, Khan FR, et al. PVT1 lncRNA in lung cancer: a key player in tumorigenesis and therapeutic opportunities[J]. Pathol Res Pract, 2024, 253: 155019. doi: 10.1016/j.prp.2023.155019
[5] Wilson C, Kanhere A. 8q24.21 locus: a paradigm to link non-coding RNAs, genome polymorphisms and cancer[J]. Int J Mol Sci, 2021, 22(3): 1094. doi: 10.3390/ijms22031094
[6] Xu Y, Luo XX, He WG, et al. Long non-coding RNA PVT1/miR-150/HIG2 axis regulates the proliferation, invasion and the balance of iron metabolism of hepatocellular carcinoma[J]. Cell Physiol Biochem, 2018, 49(4): 1403-1419.
[7] Qin S, Zhao Y, Lim G, et al. Circular RNA PVT1 acts as a competing endogenous RNA for miR-497 in promoting non-small cell lung cancer progression[J]. Biomed Pharmacother, 2019, 111: 244-250.
[8] Yang Q, Yu Y, Sun ZQ, et al. Long non-coding RNA PVT1 promotes cell proliferation and invasion through regulating miR-133a in ovarian cancer[J]. Biomed Pharmacother, 2018, 106: 61-67.
[9] Roohinejad Z, Bahramian S, Shamsabadi FT, et al. Upregulation of the c-MYC oncogene and adjacent long noncoding RNAs PVT1 and CCAT1 in esophageal squamous cell carcinoma[J]. BMC Cancer, 2023, 23(1): 34. doi: 10.1186/s12885-022-10464-z
[10] Lv HD, Zhou DX, Liu GQ. PVT1/miR-16/CCND1 axis regulates gastric cancer progression[J]. Open Med(Wars), 2023, 18(1): 20220550. doi: 10.1515/med-2022-0550
[11] Ji KY, Zhang Q, Song W, et al. LncRNA PVT1 promotes cell proliferation, invasion, and migration and inhibits cell apoptosis by phosphorylating YAP[J]. Can J Gastroenterol Hepatol, 2022, 2022: 5332129. doi: 10.1155/2022/5332129
[12] Naseri B, Farsad-Akhtar N, Mardi A, et al. lncRNA PVT1 silencing inhibits gastric cancer cells progression via enhancing chemosensitivity to paclitaxel[J]. Gene, 2025, 932: 148900. doi: 10.1016/j.gene.2024.148900
[13] Chen WL, Fan DG, Guo B, et al. The role of lncRNA PVT1 and hsa-miR-30a-3p in the development of gastric cancer[J]. Ann Clin Lab Sci, 2022, 52(2): 292-300.
[14] 陈文亮, 董静逊, 白子豪, 等. 长链非编码RNA浆细胞瘤变异易位1在胃癌中的表达及临床意义[J]. 中华实验外科杂志, 2024, 41(7): 1554-1557. CHEN Wenliang, DONG Jingxun, BAI Zihao, et al. Expression and clinical significance of long noncoding RNA plasmacytoma variant translocation 1 in gastric[J]. Chinese Journal of Experimental Surgery, 2024, 41(7): 1554-1557.
[15] Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project[J]. Gastric Cancer, 2017, 20(2): 217-225.
[16] Chahine JJ, Davis SS, Culfaci S, et al. Chromosome 8q24 amplification associated with human hepatocellular carcinoma predicts MYC/ZEB1/MIZ1 transcriptional regulation[J]. Sci Rep, 2024, 14(1): 24488. doi: 10.1038/s41598-024-75219-1
[17] Wu F, Zhu YP, Zhou CP, et al. Regulation mechanism and pathogenic role of lncRNA plasmacytoma variant translocation 1(PVT1)in human diseases[J]. Genes Dis, 2022, 10(3): 901-914.
[18] Llombart V, Mansour MR. Therapeutic targeting of “undruggable” MYC[J]. EBioMedicine, 2022, 75: 103756. doi: 10.1016/j.ebiom.2021.103756
[19] Duffy MJ, OGrady S, Tang MH, et al. MYC as a target for cancer treatment[J]. Cancer Treat Rev, 2021, 94: 102154. doi: 10.1016/j.ctrv.2021.102154
[20] Gao FY, Li XT, Xu K, et al. C-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment[J]. Cell Commun Signal, 2023, 21(1): 28. doi: 10.1186/s12964-023-01043-1
[21] Melone V, Palumbo D, Palo L, et al. LncRNA PVT1 links estrogen receptor alpha and the polycomb repressive complex 2 in suppression of pro-apoptotic genes in hormone-responsive breast cancer[J]. Cell Death Dis, 2025, 16(1): 80. doi: 10.1038/s41419-025-07423-4
[22] Shi MM, Zhang R, Lyu H, et al. Long non-coding RNAs: emerging regulators of invasion and metastasis in pancreatic cancer[J]. J Adv Res, 2025: S2090-1232(25)00073-6. doi: 10.1016/j.jare.2025.02.001
[23] Wu SH, Cheng Q, Shi Y, et al. LncRNA PVT1 activated by TGF-β1/Smad3 facilitates proliferation and metastasis of hepatocellular carcinoma via upregulating Smad6 and NRG1[J]. J Transl Med, 2025, 23(1): 500. doi: 10.1186/s12967-025-06229-4
[24] Li L, Chen J, Wang A, et al. ALKBH5 regulates ovarian cancer growth via demethylating long noncoding RNA PVT1 in ovarian cancer[J]. J Cell Mol Med, 2024, 28(2): e18066. doi: 10.1111/jcmm.18066
[25] Zeng S, Xie JH, Zeng QY, et al. lncRNA PVT1 promotes metastasis of non-small cell lung cancer through EZH2-mediated activation of hippo/NOTCH1 signaling pathways[J]. Cell J, 2021, 23(1): 21-31.
[26] Niu JT, Song XX, Zhang XM. Regulation of lncRNA PVT1 on miR-125 in metastasis of gastric cancer cells[J]. Oncol Lett, 2020, 19(2): 1261-1266.
[27] Lei Z, Zhu ZP, Yao ZH, et al. Reciprocal interactions between lncRNAs and MYC in colorectal cancer: partners in crime[J]. Cell Death Dis, 2024, 15(7): 539. doi: 10.1038/s41419-024-06918-w
[28] Tokgun O, Tokgun PE, Inci K, et al. lncRNAs as potential targets in small cell lung cancer: MYC-dependent regulation[J]. Anticancer Agents Med Chem, 2020, 20(17): 2074-2081.
[29] Tseng YY, Moriarity BS, Gong WM, et al. PVT1 dependence in cancer with MYC copy-number increase[J]. Nature, 2014, 512(7512): 82-86.
[30] Zhou YH, Gao XM, Yuan M, et al. Targeting myc interacting proteins as a winding path in cancer therapy[J]. Front Pharmacol, 2021, 12: 748852. doi: 10.3389/fphar.2021.748852
[31] Ren B, Ren J, Gu M, et al. Construction of a novel model based on PVT1-MYC duet-related genes for predicting survival and characterization of the tumor microenvironment in pancreatic cancer[J]. Front Immunol, 2024, 15: 1435593. doi: 10.3389/fimmu.2024.1435593
[32] Hao JY, Yuan B, Gou YN, et al. Prognostic value of lncRNA PVT1 for patients with gastric cancer: a meta-analysis[J]. Dis Markers, 2021, 2021: 5595965. doi: 10.1155/2021/5595965
[33] Wu HL, Wei M, Jiang XL, et al. lncRNA PVT1 promotes tumorigenesis of colorectal cancer by stabilizing miR-16-5p and interacting with the VEGFA/VEGFR1/AKT axis[J]. Mol Ther Nucleic Acids, 2020, 20: 438-450.
[34] Wang C, Zou H, Chen AP, et al. C-Myc-activated long non-coding RNA PVT1 enhances the proliferation of cervical cancer cells by sponging miR-486-3p[J]. J Biochem, 2020, 167(6): 565-575.
[1] SUN Shuangshuang, ZHANG Shuaijie, ZHANG Botao, YUAN Ying, YU Yuanyuan, XUE Fuzhong. Influencing factors of acute ischemic stroke in population during 18-50 years old: a real-world study analysis [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 40-46.
[2] LI Ziqi, WEI Yanruoxue, LIU Xiaohan, LIU Chuncheng, ZHAO Ran, LIU Yukun. The functional role and clinical significance of lncRNA HEATR3-AS1 in colorectal cancer tumorigenesis and progression [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 108-115.
[3] LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.
[4] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[5] JIA Ruoxi, LYU Li, LIU Hanyun, WU Yinping, LI Fengcai, ZHAO Zehua, WANG Kai, FAN Yuchen. Diagnostic value of blood cell count-related biomarkers in predicting 28-day mortality in acute-on-chronic hepatitis b liver failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 89-99.
[6] DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110.
[7] YANG Weifang, XU Hong, LIU Yuantao, ZHAO Huichen. Mechanism of thyroid-stimulating immunoglobulin in Graves disease recurrence and clinical significance [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 116-121.
[8] ZHANG Jie, ZHAO Yinghui, DONG Yaqi, LI Juan, LI Peilong, DU Lutao. Role of GPR133 gene methylation in predicting lymph node metastasis in early gastric cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(3): 76-84.
[9] GUO Zhenjiang, WANG Ning, ZHAO Guangyuan, DU Liqiang, CUI Zhaobo, LIU Fangzhen. Development of preoperative models for predicting positive esophageal margin in proximal gastric cancer based on machine learning [J]. Journal of Shandong University (Health Sciences), 2024, 62(7): 78-83.
[10] SUN Lina, BAI Hongyan, NIU Zongge, ZHANG Fushuai, QU Yiqing. Construction and evaluation of an online clinical risk model for predicting in-hospital mortality in patients with ARDS based on SII [J]. Journal of Shandong University (Health Sciences), 2024, 62(7): 10-20.
[11] GUO Shuhua, FAN Yang, TIAN Feng, WANG Chuanxin, DU Lutao, LI Peilong, GUO Xing, XU Shuo. Role of microfibril-associated protein 3 in regulating mesenchymal transition of glioma stem cells [J]. Journal of Shandong University (Health Sciences), 2024, 62(6): 9-16.
[12] WEI Yanruoxue, LI Ziqi, LIU Chuncheng, LIU Xiaohan, ZHAO Ran, LIU Yukun. Intratumor heterogeneity of SP1 expression in colorectal cancer and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 89-94.
[13] LIU Chuncheng, LIU Xiaohan, WEI Yanruoxue, LI Ziqi, LIU Yukun, ZHAO Ran. Subcellular localization pattern of bromodomain containing 9 in colorectal cancer and its clinical significance [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 24-30.
[14] GUO Xin, MENG Jun, ZHENG Shiliang, DONG Xiuhong. Correlation between frailty and body composition in elderly patients with gastric cancer [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 40-47.
[15] BAI Xiaoliang, SUN Panpan, WANG Hongli, GONG Shunzhi, SUN Yunqi, SHU Meng, QI Xiaoliang. Animal experiment of medical thoracoscopic splanchnotomy [J]. Journal of Shandong University (Health Sciences), 2024, 62(4): 9-13.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!